아시아 태평양 저활동성 방광 시장, 유형별(약물 치료, 수술 방법, 요도 보조 장치, 줄기 세포 및 유전자 치료), 투여 경로(경구, 비경구 및 기타), 최종 사용자(병원, 진료소, 학술 및 연구 기관 및 기타), 유통 채널(병원 약국, 소매 약국 및 기타) 산업 동향 및 2029년까지의 예측
아시아 태평양 저활동성 방광 시장 분석 및 통찰력
아시아 태평양 저활동성 방광 시장은 신경인성 방광 감염 의 증가 , 연구 자금 증가, 저활동성 방광(UAB)에 대한 새로운 치료법 개발, 파이프라인 제품으로 인한 수요 증가, R&D 투자 증가로 시장 성장과 같은 요인에 의해 주도되고 있습니다. 현재 선진국과 신흥국에서 의료비 지출이 증가하여 제조업체가 새롭고 혁신적인 제품을 개발할 수 있는 경쟁 우위를 확보할 것으로 예상됩니다. 또한 의료비 지출의 급증과 방광 장애 유병률 의 증가는 시장에 긍정적인 영향을 미칩니다.
그러나 치료 비용이 높아 환자가 고품질의 효과적인 솔루션을 수용하는 데 제한이 있습니다. 따라서 치료 절차의 비용이 높아 전체 치료 비용에 부정적인 영향을 미칩니다. 게다가 현재 UAB 치료에 사용되는 약물은 효과와 안전성 측면에서 임상적으로 만족하는 것으로 입증되지 않아 새로운 치료제 개발이 필요합니다.
아시아 태평양 저활동성 방광 시장은 시장 참여자의 증가와 새로운 파이프라인 약물의 존재로 인해 예측 기간 동안 성장할 것으로 예상됩니다. 이와 함께 제조업체는 시장에 새로운 제품을 출시하기 위한 R&D 활동에 참여하고 있습니다.
그러나 연구와 조사에 드는 비용이 높아 시장 성장이 제한될 것으로 예상되며, 이는 시장에서 신제품 출시에 더욱 영향을 미칠 수 있습니다.
연구개발 프로그램의 수가 증가하고, 혁신적이고 효과적인 치료법을 위한 새로운 개발을 촉진하기 위한 공공-민간 파트너십이 확대되면서 시장에 더욱 영향을 미치고 있습니다.
Asia-Pacific underactive bladder market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers which propelled the demand of the market in the forecast period.
Asia-Pacific underactive bladder market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyzes that Asia-Pacific underactive bladder market will grow at a CAGR of 6.0% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Type (Pharmacotherapy, Surgical Methods, Urethral Assist Device, and Stem Cell and Gene Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) |
|
Countries Covered |
Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and rest of Asia-Pacific |
|
Market Players Covered |
Astellas Pharma Inc., Aurobindo Pharma., Boehringer Ingelheim International GmbH, Macleods Pharmaceuticals Ltd., Orion Corporation, ONO PHARMACEUTICAL CO., LTD., Novartis AG, Pfizer Inc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Almirall, S.A, and Alkem Labs. among others |
Market Definition
Underactive Bladder (UAB) is a clinical condition in which urination disorder is developed as a result of reduction in the contraction of the detrusor muscle (a muscle of the bladder) during urination. It is characterized by the feeling of having to urinate immediately, and thus, this condition is different from the Overactive Bladder (OAB). The present invention provides a pharmaceutical composition useful for the prevention or treatment of UAB which has an effect of improving the urinary flow rate, an effect of improving the overdistension of the bladder (an effect of reducing bladder capacity), and is therefore, useful for the prevention or treatment of UAB.
Moreover, it is a disease state which is different from the OAB characterized by urinary urgency which has been attracting attention in recent years. Causes of UAB include autonomic neuropathy such as diabetes and alcoholism, pelvic surgery such as radical hysterectomy and radical rectal cancer, spinal cord diseases such as spina bifida, and disc herniation is also known. Patients suffering from severe and mild bladder disorder-associated problems need pharmacotherapy often cycled with multiple therapies and without adequate relief receiving continued treatments, which also creates an impact on healthcare expenditure.
Asia-Pacific Underactive Bladder Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of these are discussed in detail below:
Drivers
- Increasing prevalence of neurogenic disorders
UAB is a common neurological condition in which nerves and muscles do not work together very well resulting in prolonged urination time with or without a sensation of incomplete bladder emptying. In this condition, the detrusor muscles underperform for their contraction activity which is characterized by a slow urinary stream, hesitancy, and straining to void, with or without a feeling of incomplete bladder emptying, sometimes with storage symptoms even. Thus, the bladder either does not empty or empties only partially which is due to the bladder muscles being unable to release urine properly.
As a result, patients with UAB may have various urination symptoms and may be accompanied by a large amount of residual urine. Complications of urinary retention due to aggravation and Urinary Tract Infections (UTIs) due to chronic residual urine are often seen and have become a problem. Moreover, it is a disease state which is different from the OAB characterized by urinary urgency which has been attracting attention in recent years. Thus, the increasing prevalence of neurogenic bladder disorders is expected to drive market growth. This will lead to an increased demand for treatment that can detect patients as well, due to which there will be expected lucrative growth in the market.
- Rising healthcare expenditure
The instruments, manpower, and medical management in case of any harm to researchers, insurance, transportation, ethics committee fee, data processing, and other consumables lead to major cost involvement for the market players. The healthcare expenditure comprises all healthcare services, testing devices, family planning activities, and emergency aid designated for health. National Health Accounts provide many indicators based on expenditure collected within an internationally recognized framework. The factors determining any country's healthcare expenditure are income (per capita GDP), technological progress and variation in medical practice, and health systems characteristics.
The rise in healthcare expenditure simultaneously helps healthcare organizations and government bodies increase the research activities on menopause drugs, their upcoming clinical trials, and R&D activities. Also, the cost involved in the production and manufacturing of the new products, the market players require adequate allocation of funds and resources, hence, the government acts as a helping hand in this scenario. Growing healthcare expenditure is also beneficial for further economic development and growth of the healthcare sector. In addition, the increase in disposable income of the population is a favorable factor. Hence, rising healthcare expenditure is expected to drive market growth in the future.
Opportunity
- Rising urologic complications of diabetes
One of the known causes of UAB includes autonomic neuropathy such as diabetes. Moreover, diabetes is associated with an earlier onset and increased severity of urologic diseases that result in costly and debilitated urologic complications. These urologic complications, including bladder dysfunction and UTIs among others, have a profound effect on the quality of life of both men and women with diabetes. Diabetes and urologic diseases are very common health problems that markedly increase in prevalence and incidence with advancing age. Urologic complications of diabetes are an immediate effect. Diabetes is the most prominent disorder and has a high prevalence globally.
Diabetes-associated bladder complications can be due to an alternation in the detrusor smooth muscles, neuronal dysfunction, and urothelial dysfunction. Depending on the nerves involved, the effects of diabetic neuropathy can range from discomfort and numbness in the legs to complications with the digestive system, the urinary tract, the blood vessels, and the core. The rising data on diabetes will significantly increase the risk of urologic complications of diabetes worldwide. Thus, it is required to recommend future directions for research and clinical care for proper treatment of urologic complications of diabetes. Support from other organizations would also be required to reach the under-developed regions to tackle the neglected complications. Therefore, this signifies that the rise in urologic complications of diabetes is expected to act as an opportunity for market growth.
Restraint/Challenge
- High cost of research and development
R&D is a prerequisite in modifying the procedure intended to treat different kinds of patients. The higher cost of R&D for new products demands deep research and clinical studies. The various clinical phases in R&D require huge investments which can affect market growth. The research cost involved in planning and execution of the studies, and research requires adequate allocation of funds and resources, which can affect new developments in the market. The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased.
The high cost of the procedure is due to various checkpoints of treatments along with the use of high-tech modalities to perform such procedures. As cost of R&D for treatments is too high, it restricts accommodating high-quality and effective solutions. Henceforth, the high cost negatively impacts the cost of overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that the high cost associated with the research and studies is expected to restrain market growth which can further impact the launch of new products in the market.
Post-COVID-19 Impact on Asia-Pacific Underactive Bladder Market
COVID-19 has positively affected in the growth of the market as there is rise in the demand for products widely in the region. People have become more health conscious as there is rising prevalence of various bladder diseases in the region. Complications of urinary retention due to aggravation and UTIs due to chronic residual urine are often seen and have become a problem. Hence, COVID-19 has impacted positively on this market.
Recent Developments
- In June 2020, Vesiflo, Inc. announced the medicare coverage of inFlow urinary prosthesis, a magnetically coupled FDA-approved intraurethral valve-pump device which can be used for 29 days by adult women as an alternative to intermittent catheterization. This results in a contribution to the expansion of product business quickly with commercialization in the market.
- In April 2020, Astellas Pharma Europe Ltd. completed a clinical trial that was conducted on subjects for the treatment of underactive bladder. Currently, ASP8302 is under phase-2 clinical trial to investigate the safety and tolerability of the drug in patients with underactive bladder.
Asia-Pacific Underactive Bladder Market Scope
Asia-Pacific underactive bladder market is categorized into four notable segments based on type, route of administration, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Pharmacotherapy
- Surgical Methods
- Urethral Assist Device
- 줄기세포 및 유전자 치료
치료법을 기준으로 시장은 약물 치료, 수술적 방법, 요도 보조 장치, 줄기세포 및 유전자 치료로 구분됩니다.
투여 경로
- 경구
- 비경구적
- 기타
투여 경로를 기준으로 시장은 경구, 비경구 및 기타로 구분됩니다.
최종 사용자
- 병원
- 클리닉
- 학술 및 연구 기관
- 기타
최종 사용자를 기준으로 시장은 병원, 진료소, 학술 및 연구 기관 및 기타로 세분화됩니다.
유통 채널
- 병원 약국
- 소매 약국
- 기타
유통 채널을 기준으로 시장은 병원 약국, 소매 약국 및 기타로 구분됩니다.
아시아 태평양 저활동성 방광 시장 지역 분석/통찰력
아시아 태평양 지역의 과소활동성 방광 시장을 분석하고, 위에 언급된 대로 유형, 투여 경로, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.
아시아 태평양 저활동성 방광 시장 보고서에서 다루는 국가는 일본, 중국, 인도, 한국, 호주, 싱가포르, 말레이시아, 태국, 인도네시아, 필리핀, 베트남, 그리고 나머지 아시아 태평양 지역입니다.
- 2022년에는 아시아 태평양 지역의 저활동성 방광 시장이 방광 장애 유병률 증가와 이 지역에서 혁신적 치료법 개발을 위한 R&D 활동 증가로 시장을 장악할 것으로 예상됩니다.
중국은 방광 질환 치료를 위한 대규모 시장 참여자와 확립된 의료 시스템을 갖추고 있어 이 지역을 지배할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 하류 및 상류 가치 사슬 분석, 기술 추세, 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 아시아 태평양 저활동성 방광 시장 점유율 분석
아시아 태평양 저활동성 방광 시장 경쟁 구도는 경쟁업체의 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 아시아 태평양 지역 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 아시아 태평양 저활동성 방광 시장에 대한 회사의 초점과만 관련이 있습니다.
시장에서 운영되는 주요 업체 중 일부는 다음과 같습니다.
- 아스텔라스제약 주식회사
- 오로빈도 파마.
- 베링거인겔하임인터내셔널 GmbH
- 맥리오즈 제약 유한회사
- 오리온 주식회사
- 오노제약 주식회사
- 노바티스 AG
- 화이자 주식회사
- 주식회사 시플라
- 레디스 연구소 유한회사
- 테바제약산업주식회사
- 선제약산업주식회사
- 알미랄, SA
- 알켐랩스.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아시아 태평양 대 국가 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화해 달라고 요청하세요.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC UNDERACTIVE BLADDER MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 EPIDEMIOLOGY
4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS-
4.4.1 DOXAZOSIN
4.4.2 BETHANECHOL CHLORIDE
4.4.3 TAMSULOSIN HYDROCHLORIDE
4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER
4.5.1 EU CLINICAL TRIALS REGISTER-
4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY
4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY:
4.8 CROSS-BORDER DEALS:
4.9 OUTLOOK FOR 2022:
4.1 PATIENT ENROLMENT STRATEGIES
4.11 FACTORS AFFECTING PATIENT RECRUITMENT:
4.12 CHALLENGES:
4.13 PATIENT FUNNEL ANALYSIS:
4.14 RECOMMENDATIONS
4.14.1 USE OF TECHNOLOGY:
4.14.2 PARTICIPANT CHARACTERISTICS:
4.14.3 RECRUITER CHARACTERISTICS:
4.14.4 SYSTEMS & PROCEDURES:
4.14.5 LOCATION:
4.14.6 NATURE OF RESEARCH:
4.15 CONCLUSION:
4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM
4.17 WHAT CAUSES UNDERACTIVE BLADDER?
4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE
4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER
4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS-
5 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER
6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT
6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO
6.1.4 RISING HEALTHCARE EXPENDITURE
6.2 RESTRAINTS
6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT
6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.3 OPPORTUNITIES
6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES
6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS
6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
6.4 CHALLENGES
6.4.1 LACK OF PROPER TREATMENT
6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER
7 ASIA PACIFIC UNDERACTIVE BLADDER MARKET, BY TYPE
7.1 OVERVIEW
7.2 PHARMACOTHERAPY
7.2.1 ALPHA-BLOCKERS
7.2.2 MUSCARINIC AGONISTS
7.2.3 CHOLINESTERASE INHIBITOR
7.2.3.1 BY DRUGS
7.2.3.1.1 TAMSULOSIN
7.2.3.1.2 DOXAZOSIN
7.2.3.1.3 DISTIGMINE
7.2.3.1.4 BETHANECHOL
7.2.3.1.5 OTHERS
7.2.4 BY PRODUCT TYPES
7.2.4.1 GENERICS
7.2.4.2 BRANDED
7.2.4.2.1 FLOMAX
7.2.4.2.2 ALFADIL
7.2.4.2.3 GRAVITOR
7.2.4.2.4 URIVOID
7.2.4.2.5 OTHERS
7.3 SURGICAL METHODS
7.3.1 SURGICAL NERVE STIMULATION
7.3.2 REDUCTION CYSTOPLASTY
7.3.3 SURGERIES FOR BLADDER OBSTRUCTION
7.3.4 INJECTION INTO EXTERNAL SPHINCTER
7.3.5 OTHERS
7.4 URETHRAL ASSIS DEVICE
7.4.1 INFLOW INTRAURETHRAL VALVE PUMP
7.5 STEM CELL AND GENE THERAPIES
7.5.1 NERVE GROWTH FACTOR
7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL
7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS
8 ASIA PACIFIC UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 PARENTERAL
8.3 ORAL
8.4 OTHERS
9 ASIA PACIFIC UNDERACTIVE BLADDER MARKET , BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 CLINICS
9.4 ACADEMIC AND RESEARCH
9.5 OTHERS
10 ASIA PACIFIC UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 OTHERS
11 ASIA PACIFIC UNDERACTIVE BLADDER MARKET, BY REGION
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 INDIA
11.1.4 SOUTH KOREA
11.1.5 AUSTRALIA
11.1.6 SINGAPORE
11.1.7 THAILAND
11.1.8 INDONESIA
11.1.9 PHILIPPINES
11.1.10 MALAYSIA
11.1.11 VIETNAM
11.1.12 REST OF ASIA-PACIFIC
12 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 NOVARTIS AG
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 DR. REDDY’S LABORATORIES LTD.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ASTELLAS PHARMA INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ORION CORPORATION.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ALKEM LABS.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 ALMIRALL, S.A
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 AUROBINDO PHARMA.
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CIPLA INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GLENWOOD
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MACLEODS PHARMACEUTICALS LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 ONO PHARMACEUTICAL CO., LTD.
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 VESIFLO, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
표 목록
TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET
TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET
TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY
TABLE 4 TOTAL 58 DRUGS DISCONTINUED
TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY
TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-
TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-
TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:
TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 10 ASIA PACIFIC UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 37 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 42 ASIA-PACIFIC BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 43 ASIA-PACIFIC BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 46 ASIA-PACIFIC BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 47 ASIA-PACIFIC SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 51 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 CHINA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 CHINA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 CHINA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 CHINA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 CHINA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 58 CHINA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 59 CHINA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CHINA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 CHINA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 62 CHINA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 63 CHINA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 CHINA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 CHINA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 CHINA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 CHINA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 CHINA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 JAPAN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 JAPAN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 JAPAN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 JAPAN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 JAPAN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 74 JAPAN BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 75 JAPAN BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 JAPAN BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 JAPAN BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 78 JAPAN BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 JAPAN SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 JAPAN URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 JAPAN STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 JAPAN UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 83 JAPAN UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 JAPAN UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 INDIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 INDIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 INDIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 INDIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 INDIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 90 INDIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 91 INDIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 INDIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 INDIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 94 INDIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 95 INDIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 INDIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 INDIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 INDIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 99 INDIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 100 INDIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 101 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 SOUTH KOREA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 SOUTH KOREA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 SOUTH KOREA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 SOUTH KOREA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 106 SOUTH KOREA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 107 SOUTH KOREA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 SOUTH KOREA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 SOUTH KOREA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 110 SOUTH KOREA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 111 SOUTH KOREA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 SOUTH KOREA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 SOUTH KOREA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 115 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 AUSTRALIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 AUSTRALIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 AUSTRALIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 AUSTRALIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 122 AUSTRALIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 123 AUSTRALIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 AUSTRALIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 AUSTRALIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 126 AUSTRALIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 127 AUSTRALIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 AUSTRALIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 AUSTRALIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 131 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 132 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 133 SINGAPORE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 SINGAPORE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 SINGAPORE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 SINGAPORE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 SINGAPORE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 138 SINGAPORE BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 139 SINGAPORE BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 SINGAPORE BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 SINGAPORE BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 142 SINGAPORE BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 143 SINGAPORE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 SINGAPORE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 SINGAPORE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 SINGAPORE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 147 SINGAPORE UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 148 SINGAPORE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 149 THAILAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 THAILAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 THAILAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 THAILAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 THAILAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 154 THAILAND BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 155 THAILAND BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 THAILAND BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 THAILAND BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 158 THAILAND BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 159 THAILAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 THAILAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 THAILAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 162 THAILAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 163 THAILAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 THAILAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 INDONESIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 INDONESIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 INDONESIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 168 INDONESIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 INDONESIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 170 INDONESIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 171 INDONESIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 INDONESIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 INDONESIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 174 INDONESIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 175 INDONESIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 INDONESIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 INDONESIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 INDONESIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 179 INDONESIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 180 INDONESIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 181 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 182 PHILIPPINES PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 183 PHILIPPINES PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 184 PHILIPPINES BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 185 PHILIPPINES BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 186 PHILIPPINES BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 187 PHILIPPINES BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 PHILIPPINES BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 189 PHILIPPINES BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 190 PHILIPPINES BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 191 PHILIPPINES SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 PHILIPPINES URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 PHILIPPINES STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 195 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 196 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 197 MALAYSIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 MALAYSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 199 MALAYSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 MALAYSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 201 MALAYSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 202 MALAYSIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 203 MALAYSIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 MALAYSIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 205 MALAYSIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 206 MALAYSIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 207 MALAYSIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 MALAYSIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 MALAYSIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 MALAYSIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 211 MALAYSIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 212 MALAYSIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 213 VIETNAM UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 VIETNAM PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 215 VIETNAM PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 216 VIETNAM BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 VIETNAM BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 218 VIETNAM BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 219 VIETNAM BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 220 VIETNAM BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 VIETNAM BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 222 VIETNAM BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 223 VIETNAM SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 VIETNAM URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 VIETNAM STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 226 VIETNAM UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 227 VIETNAM UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 228 VIETNAM UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 229 REST OF ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE ASIA PACIFIC UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD
FIGURE 12 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC UNDERACTIVE BLADDER MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC UNDERACTIVE BLADDER MARKET
FIGURE 14 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : TYPE, 2021
FIGURE 15 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 16 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)
FIGURE 17 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE
FIGURE 18 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 19 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 20 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 21 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY END USER, 2021
FIGURE 23 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 24 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)
FIGURE 25 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 27 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 28 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 29 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)
FIGURE 31 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)
FIGURE 32 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)
FIGURE 35 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
